Skip to main content
Year archive

CLINUVEL PHARMACEUTICALS LIMITED — 2019 filings

All 72 regulatory filings released by CLINUVEL PHARMACEUTICALS LIMITED (CUV) in 2019, sourced directly from the official regulator.

72 Filings
2019 Period
2019 filings (72)
Filing Released Lang
SCENESSE registration dossier submitted in Australia 3 pages 156.6KB
Regulatory Filings
2019-12-22 English
Change in substantial holding 9 pages 550.2KB
Major Shareholding Notification
2019-12-09 English
Change of Director's Interest Notice 2 pages 212.6KB
Director's Dealing
2019-12-08 English
Lapse and Forfeit of Unlisted Conditional Performance Rights 2 pages 132.7KB
Regulatory Filings
2019-12-05 English
Changes in Composition to Committees 2 pages 114.5KB
Board/Management Information
2019-12-04 English
Appendix 3B 12 pages 293.3KB
Share Issue/Capital Change
2019-12-04 English
Change of Director's Interest Notice 2 pages 218.6KB
Director's Dealing
2019-12-04 English
CEO Letter 3 pages 139.7KB
Management Reports
2019-12-01 English
CLINUVEL appoints new Non-Executive Director 2 pages 151.0KB
Board/Management Information
2019-11-25 English
Initial Director's Interest Notice 2 pages 163.8KB
Director's Dealing
2019-11-25 English
Chair Address 3 pages 141.3KB
AGM Information
2019-11-19 English
Managing Directors AGM Presentation 26 pages 1.5MB
AGM Information
2019-11-19 English
Results of Meeting 2 pages 132.7KB
Declaration of Voting Results & Voting Rights Announcements
2019-11-19 English
Appendix 3B 13 pages 294.1KB
Share Issue/Capital Change
2019-11-05 English
Change of Director's Interest Notice 2 pages 221.5KB
Director's Dealing
2019-11-05 English
Appendix 4C - quarterly 8 pages 236.7KB
Interim / Quarterly Report
2019-10-30 English
Letter from the Remuneration Committee Chair 2 pages 112.9KB
Remuneration Information
2019-10-29 English
TGA Priority Registration Pathway for SCENESSE 3 pages 174.4KB
Regulatory Filings
2019-10-29 English
Notice of Annual General Meeting/Proxy Form 18 pages 405.4KB
AGM Information
2019-10-17 English
Annual Report to shareholders 82 pages 6.7MB
Environmental & Social Information
2019-10-17 English
Appendix 4G and Corporate Governance Statement 18 pages 527.5KB
Governance Information
2019-10-17 English
CLINUVEL Chair to Retire Following FDA Approval 3 pages 145.9KB
Board/Management Information
2019-10-17 English
CLINUVEL Newsletter 5 pages 248.3KB
Regulatory Filings
2019-10-16 English
Chair Letter to Shareholders 4 pages 157.1KB
Management Reports
2019-10-14 English
Audio Transcript Investor Teleconference 2 pages 128.1KB
Regulatory Filings
2019-10-09 English
FDA Grants Marketing Approval for SCENESSE 3 pages 156.1KB
Regulatory Filings
2019-10-08 English
Media Release - FDA Approves SCENESSE for Genetic Disorder 2 pages 160.9KB
Regulatory Filings
2019-10-08 English
Trading Halt 2 pages 333.7KB
Regulatory Filings
2019-10-07 English
CLINUVEL renews CEO Employment Agreement 4 pages 174.4KB
Board/Management Information
2019-10-06 English
FDA Clarifies SCENESSE PDUFA Date 2 pages 135.8KB
Regulatory Filings
2019-10-01 English
CLINUVEL Announces AGM Date 2 pages 113.7KB
AGM Information
2019-09-29 English
Initial Director's Interest Notice 2 pages 139.0KB
Director's Dealing
2019-09-24 English
CLINUVEL Appoints New Director 2 pages 118.0KB
Board/Management Information
2019-09-22 English
SCENESSE presented at ICPP in Milan 2 pages 158.2KB
Regulatory Filings
2019-09-09 English
Change of Director's Interest Notice 2 pages 186.2KB
Director's Dealing
2019-09-02 English
Appendix 4E and Preliminary Financial Report 63 pages 1.9MB
Annual Report
2019-08-27 English
CLINUVEL declares Full Year Dividend 3 pages 166.3KB
Notice of Dividend Amount
2019-08-27 English
Appendix 4E and Preliminary Financial Report Reissued 66 pages 2.0MB
Annual Report
2019-08-27 English
CLINUVEL Clarifies ex-Dividend Date 3 pages 135.1KB
Notice of Dividend Amount
2019-08-27 English
Dividend/Distribution - CUV 3 pages 26.5KB
Notice of Dividend Amount
2019-08-27 English
CLINUVEL program discussed at Light and Life 2019 Conference 2 pages 155.1KB
Regulatory Filings
2019-08-21 English
CLINUVEL Newsletter 5 pages 434.4KB
Interim / Quarterly Report
2019-08-19 English
Appendix 4C - quarterly 8 pages 436.9KB
Interim / Quarterly Report
2019-07-30 English
Change in Composition to Audit and Risk Committee 2 pages 131.6KB
Board/Management Information
2019-07-24 English
CLINUVEL Newsletter 5 pages 438.4KB
Regulatory Filings
2019-07-10 English
CLINUVEL Relocates Melbourne Office 2 pages 115.7KB
Regulatory Filings
2019-06-20 English
CLINUVEL included in S&P/ASX 200 Index 2 pages 164.6KB
Regulatory Filings
2019-06-13 English
Presentation Jefferies Healthcare Conference 13 pages 1.1MB
Investor Presentation
2019-06-06 English
Lapse and forfeit of Unlisted Conditional Performance Rights 2 pages 136.2KB
Regulatory Filings
2019-06-04 English
US FDA extends PDUFA date for SCENESSE 3 pages 171.7KB
Regulatory Filings
2019-06-02 English
Media Release-US FDA review for SCENESSE extended 3 months 3 pages 124.6KB
Regulatory Filings
2019-06-02 English
Change of Director's Interest Notice 2 pages 217.3KB
Director's Dealing
2019-05-14 English
Becoming a substantial holder 38 pages 1.9MB
Major Shareholding Notification
2019-05-07 English
CLINUVEL Newsletter 6 pages 276.4KB
Management Reports
2019-05-01 English
Appendix 4C - quarterly 8 pages 196.8KB
Interim / Quarterly Report
2019-04-29 English
Chair Letter to Shareholders 4 pages 127.1KB
Management Reports
2019-04-23 English
Presentation Goldman Sachs Emerging Leaders Conference 15 pages 991.2KB
Investor Presentation
2019-04-03 English
CLINUVEL hosts European EPP Clinical Expert Meetings 2 pages 133.3KB
Regulatory Filings
2019-03-28 English
CLINUVEL Newsletter 5 pages 266.6KB
Management Reports
2019-03-19 English
UK NICE Meeting Held 2 pages 156.2KB
Regulatory Filings
2019-03-14 English
Appendix 3B 13 pages 298.9KB
Share Issue/Capital Change
2019-03-12 English
Change of Director's Interest Notice x 3 7 pages 255.9KB
Director's Dealing
2019-03-12 English
Change in substantial holding 3 pages 154.3KB
Major Shareholding Notification
2019-03-12 English
Change in substantial holding 4 pages 460.5KB
Director's Dealing
2019-03-12 English
Investor Briefing 15 pages 1.2MB
Interim / Quarterly Report
2019-03-03 English
Appendix 4D Half Yearly Report 18 pages 1.0MB
Interim / Quarterly Report
2019-02-25 English
CLINUVEL Vitiligo Communique II 5 pages 501.9KB
Investor Presentation
2019-02-11 English
CLINUVEL Newsletter 6 pages 271.8KB
Management Reports
2019-02-06 English
Appendix 4C - quarterly 7 pages 194.5KB
Interim / Quarterly Report
2019-01-30 English
Change of Director's Interest Notice 4 pages 235.0KB
Director's Dealing
2019-01-28 English
CLINUVEL Newsletter 6 pages 358.3KB
Management Reports
2019-01-14 English
US FDA sets PDUFA date for SCENESSE 3 pages 377.1KB
Regulatory Filings
2019-01-09 English